GEP20104875B - Pyrimidine derivatives for the treatment of abnormal cell growth - Google Patents
Pyrimidine derivatives for the treatment of abnormal cell growthInfo
- Publication number
- GEP20104875B GEP20104875B GEAP20059703A GEAP2005009703A GEP20104875B GE P20104875 B GEP20104875 B GE P20104875B GE AP20059703 A GEAP20059703 A GE AP20059703A GE AP2005009703 A GEAP2005009703 A GE AP2005009703A GE P20104875 B GEP20104875 B GE P20104875B
- Authority
- GE
- Georgia
- Prior art keywords
- treatment
- cell growth
- abnormal cell
- pyrimidine derivatives
- prodrug
- Prior art date
Links
- 230000002159 abnormal effect Effects 0.000 title abstract 2
- 230000010261 cell growth Effects 0.000 title abstract 2
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
A compound of the formula (1), or a pharmaceutically acceptable salt thereof, solvate, hydrate or prodrug, (values R1, R2, R3, R4, and n are as defined in the description), a pharmaceutical composition containing them and use thereof for treatment of abnormal cell growth.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57131204P | 2004-05-14 | 2004-05-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GEP20104875B true GEP20104875B (en) | 2010-01-11 |
Family
ID=34966230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GEAP20059703A GEP20104875B (en) | 2004-05-14 | 2005-05-02 | Pyrimidine derivatives for the treatment of abnormal cell growth |
Country Status (27)
| Country | Link |
|---|---|
| EP (1) | EP1751143A1 (en) |
| JP (1) | JP4099212B2 (en) |
| KR (1) | KR100886990B1 (en) |
| CN (2) | CN102127058A (en) |
| AP (1) | AP2241A (en) |
| AR (1) | AR049097A1 (en) |
| AU (2) | AU2005243397A1 (en) |
| BR (1) | BRPI0511138A (en) |
| CA (1) | CA2566707A1 (en) |
| CR (1) | CR8749A (en) |
| EA (1) | EA200601796A1 (en) |
| EC (1) | ECSP066997A (en) |
| GE (1) | GEP20104875B (en) |
| GT (1) | GT200500113A (en) |
| IL (1) | IL178828A0 (en) |
| MA (1) | MA28583B1 (en) |
| MX (1) | MXPA06011890A (en) |
| NL (2) | NL1029045C2 (en) |
| NO (1) | NO20064576L (en) |
| NZ (1) | NZ550448A (en) |
| PA (1) | PA8632601A1 (en) |
| PE (1) | PE20060240A1 (en) |
| TN (1) | TNSN06370A1 (en) |
| TW (1) | TWI303635B (en) |
| UY (1) | UY28894A1 (en) |
| WO (1) | WO2005111023A1 (en) |
| ZA (1) | ZA200608394B (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4812763B2 (en) * | 2004-05-18 | 2011-11-09 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Cycloalkyl-substituted pyrimidinediamine compounds and uses thereof |
| US20070032514A1 (en) * | 2005-07-01 | 2007-02-08 | Zahn Stephan K | 2,4-diamino-pyrimidines as aurora inhibitors |
| EP1966207A2 (en) * | 2005-12-21 | 2008-09-10 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
| DK2146779T3 (en) * | 2007-04-18 | 2016-11-28 | Pfizer Prod Inc | Sulfonylamid derivatives to treat abnormal cell growth. |
| CN101903357A (en) * | 2007-07-17 | 2010-12-01 | 里格尔药品股份有限公司 | Cyclic amine-substituted pyrimidinediamines as PKC inhibitors |
| US8461147B2 (en) * | 2007-12-03 | 2013-06-11 | Boehringer Ingelheim International Gmbh | Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation |
| JP2011523646A (en) * | 2008-05-21 | 2011-08-18 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Phosphorus derivatives as kinase inhibitors |
| US8410126B2 (en) * | 2009-05-29 | 2013-04-02 | Boehringer Ingelheim International Gmbh | Pyrimidine inhibitors of PKTK2 |
| US8729265B2 (en) | 2009-08-14 | 2014-05-20 | Boehringer Ingelheim International Gmbh | Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives |
| US8933227B2 (en) | 2009-08-14 | 2015-01-13 | Boehringer Ingelheim International Gmbh | Selective synthesis of functionalized pyrimidines |
| US20120244141A1 (en) | 2010-09-28 | 2012-09-27 | Boehringer Ingelheim International Gmbh | Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors |
| WO2014174745A1 (en) * | 2013-04-26 | 2014-10-30 | 国立大学法人京都大学 | Eg5 INHIBITOR |
| CN109608444B (en) * | 2018-11-27 | 2022-02-11 | 中国药科大学 | ERK inhibitor containing isoindolinone and preparation method and use thereof |
| CN111732548B (en) * | 2020-06-11 | 2022-06-17 | 浙江大学 | N2-carbamyl aromatic ring-2-aminopyrimidine derivatives and medical application thereof |
| WO2024140671A1 (en) * | 2022-12-29 | 2024-07-04 | 南京昕瑞再生医药科技有限公司 | Fused tricyclic derivative, pharmaceutical composition comprising same, and use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9721437D0 (en) * | 1997-10-10 | 1997-12-10 | Glaxo Group Ltd | Heteroaromatic compounds and their use in medicine |
| AR042586A1 (en) | 2001-02-15 | 2005-06-29 | Sugen Inc | 3- (4-AMIDOPIRROL-2-ILMETILIDEN) -2-INDOLINONE AS INHIBITORS OF PROTEIN KINASE; YOUR PHARMACEUTICAL COMPOSITIONS; A METHOD FOR THE MODULATION OF THE CATALYTIC ACTIVITY OF PROTEINQUINASE; A METHOD TO TREAT OR PREVENT AN AFFECTION RELATED TO PROTEINQUINASE |
| WO2003030909A1 (en) * | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| SI1625121T1 (en) * | 2002-12-20 | 2010-04-30 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| UA80767C2 (en) * | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
-
2005
- 2005-05-02 EA EA200601796A patent/EA200601796A1/en unknown
- 2005-05-02 CN CN2011100212904A patent/CN102127058A/en active Pending
- 2005-05-02 NZ NZ550448A patent/NZ550448A/en not_active IP Right Cessation
- 2005-05-02 BR BRPI0511138-2A patent/BRPI0511138A/en not_active IP Right Cessation
- 2005-05-02 MX MXPA06011890A patent/MXPA06011890A/en unknown
- 2005-05-02 AP AP2006003790A patent/AP2241A/en active
- 2005-05-02 AU AU2005243397A patent/AU2005243397A1/en not_active Abandoned
- 2005-05-02 KR KR1020067023767A patent/KR100886990B1/en not_active Expired - Lifetime
- 2005-05-02 CN CNA2005800155302A patent/CN1953974A/en active Pending
- 2005-05-02 CA CA002566707A patent/CA2566707A1/en not_active Abandoned
- 2005-05-02 WO PCT/IB2005/001201 patent/WO2005111023A1/en not_active Ceased
- 2005-05-02 GE GEAP20059703A patent/GEP20104875B/en unknown
- 2005-05-02 JP JP2007512557A patent/JP4099212B2/en not_active Expired - Lifetime
- 2005-05-02 EP EP05732043A patent/EP1751143A1/en not_active Withdrawn
- 2005-05-11 PA PA20058632601A patent/PA8632601A1/en unknown
- 2005-05-11 TW TW094115237A patent/TWI303635B/en not_active IP Right Cessation
- 2005-05-12 PE PE2005000534A patent/PE20060240A1/en not_active Application Discontinuation
- 2005-05-12 UY UY28894A patent/UY28894A1/en not_active Application Discontinuation
- 2005-05-13 NL NL1029045A patent/NL1029045C2/en not_active IP Right Cessation
- 2005-05-13 AR ARP050101969A patent/AR049097A1/en not_active Application Discontinuation
- 2005-05-13 GT GT200500113A patent/GT200500113A/en unknown
-
2006
- 2006-05-19 NL NL1031845A patent/NL1031845C2/en not_active IP Right Cessation
- 2006-10-06 ZA ZA200608394A patent/ZA200608394B/en unknown
- 2006-10-09 NO NO20064576A patent/NO20064576L/en not_active Application Discontinuation
- 2006-10-23 IL IL178828A patent/IL178828A0/en unknown
- 2006-11-13 CR CR8749A patent/CR8749A/en not_active Application Discontinuation
- 2006-11-13 TN TNP2006000370A patent/TNSN06370A1/en unknown
- 2006-11-13 EC EC2006006997A patent/ECSP066997A/en unknown
- 2006-11-14 MA MA29452A patent/MA28583B1/en unknown
-
2009
- 2009-11-13 AU AU2009238255A patent/AU2009238255A1/en not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEP20084357B (en) | Pyrimidine derivatives for the treatment of abnormal cell growth | |
| GEP20094605B (en) | Pyrazole derivatives, compositions containing such compounds and methods of use thereof | |
| GEP20084341B (en) | Aminoheteroaryl compounds as protein kinase inhibitors | |
| GEP20104895B (en) | Preparation of pregabalin and related compounds | |
| GEP20125456B (en) | Azetidines as mek inhibitors for the treatment of proliferative diseases | |
| MY139302A (en) | Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | |
| WO2006084017A3 (en) | Phenyl-substituted pyrimidine compounds useful as kinase inhibitors | |
| GEP20156282B (en) | Compounds and compositions as protein kinase inhibitors | |
| SE0202463D0 (en) | Novel compounds | |
| TW200740758A (en) | Benzoquinazoline derivatives | |
| ATE450533T1 (en) | CARBOXAMIDE DERIVATIVES | |
| MXPA05012415A (en) | Isoquinoline derivatives and their use as gfat inhibitors. | |
| MY137156A (en) | Dual nk1/nk3 derivatives | |
| MX2007003546A (en) | Indozolone derivatives as 11b-hsd1 inhibitors. | |
| MX2007010532A (en) | 1- sulfonyl-pi perdine- 3 -carboxyl i c acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type ii diabetes mellitus. | |
| TW200642689A (en) | Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient | |
| MXPA06013164A (en) | Pyrimidines derivatives for the treatment of abnormal cell growth. | |
| TW200732303A (en) | Novel fused pyrrole derivatives | |
| MY186650A (en) | Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives | |
| MY140630A (en) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| UA89787C2 (en) | Fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof | |
| MX2007013624A (en) | Protein kinase inhibitors. | |
| AU2003250471A8 (en) | Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors | |
| TW200504029A (en) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| MX2007004302A (en) | Pi3 kinase gamma inhibitors for the treatment of anaemia. |